Supplementary Materials

Supplementary Material for:

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

Juan Fu, David B. Kanne, Meredith Leong, Laura Hix Glickman, Sarah M. McWhirter, Edward Lemmens, Ken Mechette, Justin J. Leong, Peter Lauer, Weiqun Liu, Kelsey E. Sivick, Qi Zeng, Kevin C. Soares, Lei Zheng, Daniel A. Portnoy, Joshua J. Woodward, Drew M. Pardoll, Thomas W. Dubensky Jr.,* Young Kim*

*Corresponding author. E-mail: ykim76{at} (Y.K.); tdubensky{at} (T.W.D.J.)

Published 15 April 2015, Sci. Transl. Med. 7, 283ra52 (2015)
DOI: 10.1126/scitranslmed.aaa4306

This PDF file includes:

  • Materials and Methods
  • Fig. S1. CDNs can induce cellular and humoral immunity.
  • Fig. S2. CDNs are more potent adjuvants than TLR agonists.
  • Fig. S3. CDNs do not kill tumor cells directly.
  • Fig. S4. CDA and CDG are equally effective when formulated into STINGVAX.
  • Fig. S5. CDNs with dithiophosphate backbone can be synthesized.
  • Fig. S6. 2′-3′ linkage did not have improved antitumor efficacy in the murine system.
  • Fig. S7. PD-L1 induction with STINGVAX treatment is IFNγ-dependent.
  • Fig. S8. STINGVAX-treated mice become immune to repeat tumor challenge.
  • Reference (44)

[Download PDF]